LGVN

Equity

Longeveron Inc.

Health Care · Biotechnology

$0.54

+0.54 (+0.00%)

Open

N/A

Day Range

$0.54 - $0.59

52W Range

$0.49 - $1.92

Volume

266K

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Trial Results from LGVN Continue to Impress

Zacks Small Cap Research 1 day ago

Sector Update: Health Care Stocks Edge Higher Wednesday Afternoon

MT Newswires 2 days ago

Longeveron Shares Fall After Releasing Phase 2b Data From Age-Related Frailty Study

MT Newswires 2 days ago

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

GlobeNewswire 2 days ago

LGVN Announces New CEO and Cost Cuts

Zacks Small Cap Research Feb 17, 2026

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
ABCL AbCellera Biologics Inc. $3.61 N/A - +0.00%
ABUS Arbutus Biopharma Corporation $4.66 N/A - +0.00%
001540.KQ AHN-GOOK PHA $8,070.00 N/A 5.45% +0.00%
AKBA Akebia Therapeutics, Inc. $1.31 N/A - +0.00%
AHCO AdaptHealth Corp. $9.15 N/A - +0.00%
ABBV AbbVie Inc. $232.08 N/A 2.87% +0.00%
ACAD ACADIA Pharmaceuticals Inc. $24.56 N/A - +0.00%
CRSP CRISPR Therapeutics AG $60.14 N/A - +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About Longeveron Inc.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

longeveron.com →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

50

Borderline

Based on 4 fundamental factors

Analysis Tools

Sign in for analysis tools

Share